Lithium for bipolar disorder: A re-emerging treatment for mood instability

Current Psychiatry

Volumn 13, Issue 6, 2014, Pages 39-44

  McInnis, Melvin G ^a   Thomas, B ^a   Woodworth, Nancy Upjohn ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

ABDOMINAL DISCOMFORT; ACNE; ALOPECIA; ARTICLE; ATAXIA; BIOCHEMISTRY; BIPOLAR DISORDER; DIABETES INSIPIDUS; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSGEUSIA; HUMAN; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MENTAL DEFICIENCY; MENTAL INSTABILITY; MYELOPROLIFERATIVE DISORDER; NAUSEA; POLYDIPSIA; POLYURIA; STRATEGIC PLANNING; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; XEROSTOMIA;

EID: 84902462527     PISSN: 15378276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Shorter E. The history of lithium therapy. Bipolar Disord. 2009;11(11 suppl 2):4-9.
2. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York, NY: Oxford University Press; 2007.
3. Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001:CD003013.
4. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry. 2000; 57(5): 481-489.
5. Bowden CL, Calabrese JR, Sachs G, et al; Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60(4): 392-400.
6. Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002; 26(4): 530-536.
7. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1): 62-69.
8. Perlis RH, Smoller JW, Ferreira MA, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009; 166(6): 718-725.
9. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10): 942-947.
10. Duffy A, Alda M, Kutcher S, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry. 2002;63(12): 1171-1178.
11. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003; 290(11): 1467-1473.
12. Quiroz JA, Machado-Vieira R, Zarate CA Jr, et al. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010; 62(1): 50-60.
13. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011; 198(5): 351-356.
14. de Sousa RT, van de Bilt MT, Diniz BS, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett. 2011; 494(1): 54-56.
15. Nierenberg AA, Sylvia LG, Leon AC, et al; LiTMUS Study Group. Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials. 2009; 6(6): 637-648.
16. Sylvia LG, Reilly-Harrington NA, Leon AC, et al. Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment-Moderate dose Use Study (LiTMUS) for bipolar disorder. Clin Trials. 2012; 9(1): 94-101.
17. McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010; 11(10): 1439-1465.
18. Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy [published online February 15, 2014]. Pharmacol Biochem Behav. doi: 10.1016/j.pbb.2014.02.004.
19. Berridge MJ. Unlocking the secrets of cell signaling. Annu Rev Physiol. 2005; 67: 1-21.
20. Devaki R, Shankar Rao S, Nadgir SM. The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain. J Psychiatry Neurosci. 2006; 31(4): 246-252.
21. Pan JQ, Lewis MC, Ketterman JK, et al. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology. 2011; 36(7): 1397-1411.
22. Hu LW, Kawamoto EM, Brietzke E, et al. The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(1): 11-17.
23. Chen HM, DeLong CJ, Bame M, et al. Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients [published online March 25, 2014]. Transl Psychiatry. doi:10.1038/tp.2014.12.
24. Jefferson JW. Lithium. In: Aronson JK, ed. Side effects of drugs annual, volume 26. Amsterdam, The Netherlands: Elsevier Science; 2003:19-29.
25. Baldessarini RJ, Tondo L, Floris G, et al. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord. 2000; 61(2): 13-22.
26. Baldessarini RJ, Tondo L, Hennen J, et al. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord. 1999; 1(2): 91-97.
27. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry. 1976; 133(8): 925-929.
28. Peck CC, Pond SM, Becker CE, et al. An evaluation of the effects of lithium in the treatment of chronic alcoholism. II. Assessment of the two-period crossover design. Alcohol Clin Exp Res. 1981; 5(2): 252-255.
29. Peselow ED, Dunner DL, Fieve RR, et al. Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients. Am J Psychiatry. 1982; 139(6): 747-752.
30. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008; 22(8): 671-692.
31. Alevizos B, Alevizos E, Leonardou A, et al. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study. Psychiatrike. 2012; 23(2): 143-148.
32. Goldberg JF, Sacks MH, Kocsis JH. Low-dose lithium augmentation of divalproex in geriatric mania. J Clin Psychiatry. 2000;61(4):304.
33. Saunders KE, Goodwin GM. New approaches in the treatment of bipolar depression. Curr Top Behav Neurosci. 2013; 14: 291-307.
34. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011; 198(5): 351-356.
35. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133: 429-435.
36. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004; 34(1): 73-82.
37. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9): 606-613.
38. Altman EG, Hedeker D, Peterson JL, et al. The Altman Self-Rating Mania Scale. Biol Psychiatry. 1997; 42(10): 948-955.
39. Machado-Vieira R, Luckenbaugh DA, Soeiro-de-Souza MG, et al. Early improvement with lithium in classic mania and its association with later response. J Affect Disord. 2013;144(1-2):160-164.
40. Severus WE, Lipkovich IA, Licht RW, et al. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorde. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry. 2010; 25(8): 443-449.
41. Vestergaard P, Licht RW, Brodersen A, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand. 1998; 98(4): 310-315.
42. Nierenberg AA, Friedman ES, Bowden CL, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry. 2013;170(1):102-111